Clinical Trials Logo

Filter by:
NCT ID: NCT03191825 Recruiting - Clinical trials for Nicotine Dependence, Cigarettes

Online Lapse Management Intervention

Start date: September 12, 2017
Phase: N/A
Study type: Interventional

The purpose of the trial is to test the adjunctive effect of adding a lapse management system to a best practices web- and mobile smoking cessation program.

NCT ID: NCT03191279 Not yet recruiting - Trauma Clinical Trials

First Aid by Laypersons - Effect on Mortality and Length of Stay

Start date: August 2018
Phase: N/A
Study type: Observational

The study aims to assess the effect of first aid from bystanders on survival, admission length, and need of ICU-stay for trauma victims.

NCT ID: NCT03188354 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkins Lymphoma (NHL) with rising incidence and variable response to treatment. MRI is considered the most useful imaging modality of PCNSL, but conventional MRI has its limitations, and contrast-enhanced MRI sometimes does not clearly differentiate PCNSL from other neoplasm or non-neoplastic diseases. Positron emission tomography (PET) could have a number of potential advantages in refining and improving the management of patients with PCNSL. Because of the rare incidence of PCNSL, the value of PET has however not been well defined in this subtype of lymphomas. There are a few studies that have investigated the role for FDG-PET and amino acid PET in the primary staging/diagnosis and response assessment in PCNSL patients, but the results are inconclusive. Further studies are therefore needed. Previous studies support an integration of both MRI and PET for the routine diagnostic workup and response assessment for PCNSL, and the newly available simultaneous PET/MRI scanners may have the potential to improve imaging baseline accuracy, response assessment and add prognostic value in PCNSL. The main aim of the study is to compare the sensitivity and specificity of a combined PET/MRI examination with the clinical routine MRI examination given to these patients today. It will be investigated whether PET (18F-FDG and 18F-fluciclovine) can provide additional prognostic value at baseline and in response assessment compared to MRI and established pre-treatment prognostic scores in PCNSL, and evaluate which PET/MRI parameters that are best suited as an imaging biomarker for progression-free survival.

NCT ID: NCT03187613 Completed - Retinal Detachment Clinical Trials

Correlation of Metamorphopsia and Aniseikonia to Retinal Shift Following Retinal Detachment Surgery

Start date: June 21, 2017
Phase:
Study type: Observational

Individuals operated for rhegmatogenous retinal detachment will be prospectively evaluated for postoperative retinal shift. Fundus autofluorescence will be used to evaluate retinal shift that will be correlated to visual acuity, metamorphopsia, aniseikonia, and stereopsis.

NCT ID: NCT03186729 Recruiting - Atrial Fibrillation Clinical Trials

Study of Antithrombotic Treatment After IntraCerebral Haemorrhage

STATICH
Start date: July 1, 2018
Phase: Phase 4
Study type: Interventional

The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.

NCT ID: NCT03184571 Completed - NSCLC Stage IV Clinical Trials

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Start date: October 17, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in up to 106 participants with previously treated, advanced adenocarcinoma of the lung. The study will enroll three cohorts of participants with previously treated, advanced adenocarcinoma of the lung: Cohort A will consist of participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of participants who received a maximum of one prior line of an anti-programmed death receptor (PD)-(L)1 therapy (monotherapy). Cohort C will consist of participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.The primary objective is to assess the anti-tumor activity of bemcentinib and pembrolizumab when given in combination.

NCT ID: NCT03184558 Terminated - Clinical trials for Triple Negative Breast Cancer

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.

NCT ID: NCT03183323 Completed - Clinical trials for Chronic Kidney Diseases

Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure

ITISHOPE4HF
Start date: June 8, 2017
Phase: N/A
Study type: Interventional

ITISHOPE4HF is a randomized controlled trial of telerehabilitation in a heart failure population. The goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients. Patients will be provided telerehabilitation or advice on physical activity (standard care).

NCT ID: NCT03182907 Completed - Clinical trials for Clostridium Difficile Infection

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

MODIFY III
Start date: March 27, 2018
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug treatment. The primary hypothesis is that the area under the concentration-time curve from 0 to infinity (AUC0-inf) of bezlotoxumab after treatment of pediatric participants with bezlotoxumab is similar when compared to the AUC0-inf of bezlotoxumab after treatment of adults with bezlotoxumab.

NCT ID: NCT03182491 Active, not recruiting - Allergy Clinical Trials

Mechanisms of Anaphylaxis

ANAMEK
Start date: April 28, 2017
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome. The study participants are patients with anaphylaxis, patients with mild allergic reactions, and patients with febrile transfusion reactions. The investigators will also include a group of healthy controls.